Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalation of Octreotide-LAR in Acromegaly
NCT00461149Phase 4Completed
- Sponsor
- University of Naples Federico II
- Start
- Jan 1995
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of octreotide LAR in acromegaly, sponsored by University of Naples Federico II. Primary endpoints: Growth Hormone and Insulin-like Growth Factor I control at 24 months and Tumor shrinkage at 24 months. Started Jan 1995; status: completed.
02
Drugs
octreotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00461149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00461149.